Scientists from AstraZeneca, the British-based pharmaceutical group, are in talks with the US health authorities about the possibility of developing a vaccine for swine flu.
The staff work for the company's MedImmune subsidiary, which was bought for $15bn (£10bn) two years ago, and already produces an intra-nasal treatment for other strains of flu under the FluMist banner.
Simon Lowth, finance director of AstraZeneca, warned that even if it was decided a vaccine was needed it could be months before it was developed, given the particular strain of flu had still to be identified. "Our scientists are in close contact with the US Centre for Disease Control ... first they will need to get feedback and then they will need to deliver a vaccine," he explained.
http://www.guardian.co.uk/world/2009/apr/30/swine-flu-vacine-talks
Printer-friendly format
Email this thread to a friend
Bookmark this thread
(1000+ posts)
Send PM |
Profile |
Ignore
